Welcome to our dedicated page for Processa Pharmaceuticals SEC filings (Ticker: PCSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Processa Pharmaceuticals, Inc. (PCSA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage pharmaceutical company listed on the Nasdaq Capital Market, Processa uses filings such as Forms 8-K, proxy statements, and registration statements to report material events related to its capital structure, shareholder votes, financing transactions, and listing status.
Recent Form 8-K filings detail key corporate actions, including a 1-for-25 reverse stock split of issued and outstanding common shares implemented through a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation. The filings explain that the reverse split became effective in December 2025, that the par value of the common stock was unchanged, and that the stock continued to trade on Nasdaq under the PCSA symbol with a new CUSIP number. Earlier 8-K and 8-K/A filings describe shareholder approval of amendments to increase authorized common shares from 100,000,000 to 1,000,000,000 and to authorize a reverse stock split within a specified ratio range.
Filings also address Nasdaq listing compliance. In an 8-K dated August 8, 2025, Processa reported receiving a second 180-day grace period from Nasdaq to regain compliance with the $1.00 minimum bid price requirement, and noted that it might implement a reverse stock split to cure the deficiency. Additional 8-Ks and the definitive proxy statement (DEF 14A) provide details on special meetings of stockholders, quorum issues, adjournments, and final voting results on proposals related to authorized share increases, the reverse stock split, and amendments to the company’s omnibus incentive plan.
Capital-raising activities are also documented in SEC filings. For example, an 8-K filed in June 2025 describes the pricing of a public offering of common stock (and pre-funded warrants in lieu thereof) with associated common warrants, stating that net proceeds are intended to support the Phase 2 NGC-Cap trial and general corporate purposes. Another 8-K filed in August 2025 outlines a private placement securities purchase agreement with an accredited investor, including gross proceeds, use of proceeds for general corporate purposes, and placement agent compensation.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight the most important points from each document, such as changes to authorized shares, reverse stock split terms, Nasdaq notices, and financing structures. Users can quickly see how each filing affects Processa’s capital structure, listing status, and governance, while still having the option to review the full text of the original SEC documents. As additional quarterly and annual reports (Forms 10-Q and 10-K), proxy statements, and Form 4 insider transaction reports become available on EDGAR, they are incorporated into this page with real-time updates and plain-language explanations.
Neal James R, a Director of Processa Pharmaceuticals, Inc. (PCSA), reported issuance of equity awards dated 10/01/2025. The Form 4 shows 100,000 Restricted Stock Units (RSUs) granted with a reported value of $0 and 300,000 stock options granted with a conversion/exercise price of $0.198. Following the reported transactions the reporting person beneficially owns 100,000 RSUs and 300,000 options, each held directly. The RSUs vest one-third on 10/01/2026 and then one-thirty-sixth monthly until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant, with the remainder vesting ratably over the next two years. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person and dated 10/03/2025.
Processa Pharmaceuticals, Inc. (PCSA) director Khoso Baluch reported receipt on 10/01/2025 of equity awards: 100,000 Restricted Stock Units and 300,000 stock options with an exercise price of $0.198. Following the grants, the reporting person beneficially owns 100,000 RSUs and 300,000 options directly.
The RSUs vest one-third on 10/01/2026 and then monthly over the following 24 months until fully vested on 10/01/2028. The stock options vest one-third on the first anniversary of the grant, with the remainder vesting ratably over the next two years. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Geraldine Pannu, a director of Processa Pharmaceuticals, Inc. (PCSA), reported grants on 10/01/2025 consisting of 100,000 restricted stock units (RSUs) and 300,000 stock options with an exercise price of $0.198. The RSUs vest one-third on 10/01/2026 and then monthly over two additional years until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant with the remainder vesting ratably over the next two years. Following these grants, Ms. Pannu beneficially owns 100,000 shares represented by the RSUs and has rights to acquire 300,000 shares via options. The Form 4 was signed on 10/03/2025 by an attorney-in-fact on her behalf.
Processa Pharmaceuticals, Inc. (PCSA) reported a Form 4 showing that director Justin W. Yorke received equity awards dated 10/01/2025. The filing discloses 100,000 Restricted Stock Units (RSUs) and 300,000 stock options granted to Mr. Yorke. The RSUs vest one-third on 10/01/2026 and then monthly in one-thirty-sixths until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant with the remainder vesting ratably over the following two years. Price terms shown are $0 for the RSUs and $0.198 exercise price for the options. The report was signed on 10/03/2025.
Wendy Guy, listed as Chief Administrative Officer and a director of Processa Pharmaceuticals, Inc. (PCSA), reported equity awards dated 10/01/2025. The Form 4 shows the grant of 50,000 Restricted Stock Units (RSUs) and 150,000 stock options with an exercise price of $0.198. Following the transactions, she beneficially owns 50,000 RSUs and 150,000 options directly.
The RSUs vest one-third on 10/01/2026 and then vest monthly (one‑thirty‑sixth) until fully vested on 10/01/2028. The stock options vest one‑third on the first anniversary of the grant and the remainder vests ratably over the following two years.
Processa Pharmaceuticals, Inc. (PCSA) reported insider awards to Patrick Lin, its Chief Business - Strategy Officer. On 10/01/2025 Mr. Lin was granted 68,000 Restricted Stock Units (RSUs) and 204,000 stock options with an exercise price of $0.198. The RSUs convert one-for-one to common shares and vest one-third on 10/01/2026 with the remainder vesting monthly through 10/01/2028. The options vest one-third on the first anniversary of the grant with the balance vesting ratably over the next two years. The Form 4 was signed via power of attorney on 10/03/2025.
Processa Pharmaceuticals, Inc. (PCSA) reported insider awards to Chief Development Officer Sian Bigora. On 10/01/2025 Ms. Bigora was granted 96,000 restricted stock units and 288,000 stock options with an exercise price of $0.198. The RSUs vest one-third on 10/01/2026 and then monthly over two years until fully vested on 10/01/2028. The options vest one-third on the first anniversary of the grant with the remainder vesting ratably over the next two years. Following the grants, Ms. Bigora beneficially owns 96,000 shares and 288,000 option shares, reported as direct ownership.
Processa Pharmaceuticals (PCSA) reported a Form 4 for its Chief Financial Officer, reflecting equity grants dated October 1, 2025. The filing shows an award of 108,000 Restricted Stock Units (RSUs) and stock options for 324,000 shares at an exercise price of $0.198 per share.
The RSUs vest one-third on October 1, 2026, then one-thirty-sixth each month until fully vested on October 1, 2028. The options vest one-third on the first anniversary of the grant date, with the remainder vesting ratably over the following two years. After these transactions, the filing lists 108,000 RSUs and 324,000 options beneficially owned, held directly.
David Young, President of Research & Development and a director at Processa Pharmaceuticals, Inc. (PCSA), reported equity awards granted on 10/01/2025. The filing shows 111,000 Restricted Stock Units granted, each converting to one share upon vesting: one-third vests on 10/01/2026 and the remainder vests monthly over two years until 10/01/2028. It also reports 333,000 stock options with an exercise price of $0.198; those options vest one-third on the first anniversary of the grant and the remainder ratably over the next two years. Following the transactions the reporting person beneficially owns the awarded 111,000 RSUs and 333,000 options. The Form is signed by an attorney-in-fact on 10/03/2025.
Processa Pharmaceuticals (PCSA) reported insider grants to CEO and director George Ng dated 10/01/2025. He was awarded 256,000 restricted stock units (RSUs) that vest one‑third on 10/01/2026 and then monthly over two years until fully vested on 10/01/2028. He also received 768,000 stock options with an exercise price of $0.198, vesting one‑third on the first anniversary and the remainder ratably over the next two years. Both awards are reported as directly owned following the grants. The Form 4 was signed on behalf of Mr. Ng by an attorney‑in‑fact and shows no dispositions or other securities changes.